drugset / Trial / NCT01529294

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

NCT01529294

Phase 1 Completed 90 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-label

Summary

This study aims to determine the pharmacokinetic profile and the tolerability of iloperidone in subjects with mild or moderate hepatic impairment comparatively to healthy matched subjects

Timeline

Start
2010-08
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule 2 mg Oral

Indications

No indication recorded.